Mativ Holdings, Inc. (MATV) Stock Analysis and Metrics

Mativ Holdings

NYSE: MATV

$8.13 ▲ +0.28 (+3.57%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap447.40 Mn

P/E5.86

P/S0.23

Div. Yield0.01

ROIC (Qtr)-0.07

Total Debt (Qtr)1.04 Bn

Revenue Growth (1y) (Qtr)-1.07

Add ratio to table…

About

Mativ Holdings, Inc. is a global specialty materials company focused on advanced filtration and adhesive technologies. The company designs, manufactures, and markets performance materials used across industrial, consumer, and healthcare applications. Its core operations center on developing high-value solutions that enhance product functionality, durability, and efficiency for downstream manufacturers and end-users.

Mativ Holdings, Inc. generates revenue through the sale of specialty materials and engineered products to industrial and commercial customers. Primary offerings include filtration media, adhesive tapes, labels, and functional films that are integrated into customer manufacturing processes or end products. The company serves a diverse base of manufacturers in sectors such as transportation, healthcare, packaging, and consumer goods, where its materials contribute to performance, safety, and sustainability attributes.

The company operates through the following segments: Filtration and Advanced Materials (FAM) and Sustainable and Adhesive Solutions (SAS).

• Filtration and Advanced Materials: This segment produces high-performance filtration media and specialty materials used in liquid and air filtration applications. Key product lines include melt-blown, spun-bond, and composite fabrics designed for industrial filters, medical masks, and protective apparel. The segment also manufactures advanced materials such as nanofiber webs and coated substrates that meet stringent performance standards in demanding environments.

• Sustainable and Adhesive Solutions: This segment focuses on pressure-sensitive adhesives, tapes, labels, and sustainable bonding solutions for industrial and consumer applications. It produces single- and double-coated tapes, release liners, and specialty label materials used in assembly, packaging, and product identification. The segment emphasizes recyclable, solvent-free, and bio-based adhesive technologies to support customer sustainability goals.

Mativ Holdings, Inc. holds a competitive position in the global specialty materials market, particularly in niche filtration and adhesive segments where technical performance and customization are critical. The company differentiates itself through proprietary material science, integrated manufacturing capabilities, and long-term relationships with industrial customers. While facing competition from large diversified chemical and materials firms, Mativ leverages its focused product portfolios and application expertise to maintain relevance in high-value, low-volume markets where performance specifications outweigh price sensitivity.

Mativ Holdings, Inc. serves industrial manufacturers, converters, and original equipment manufacturers across multiple end-markets. Key customer industries include automotive, healthcare, packaging, and consumer goods producers who integrate Mativ’s materials into their production lines or final products. The company’s materials are often embedded in components such as filters, medical devices, transportation interiors, and sustainable packaging solutions, supporting functionality, compliance, and performance requirements.

Investment Thesis

▲ Bull case

Mativ’s recent strategic initiatives are positioning the company for accelerated growth in high-margin adjacent markets, particularly through its new aerospace specialty films commitment, which management confirmed will begin contributing in Q2 2026 and ramp through the second half of the year. This development exemplifies the company’s ability to leverage existing process capabilities and technical expertise to enter premium applications where its materials enable critical performance in life-saving or high-reliability systems. Unlike commoditized segments, aerospace applications typically command pricing power, longer contract durations, and lower elasticity to economic cycles, offering a structural shift toward higher-margin revenue streams. The fact that this win emerged from cross-functional collaboration signals that Mativ’s R&D and commercial teams are now effectively aligned to identify and capture white space opportunities, a capability that was historically underutilized. As the company continues to prioritize high-return projects in its innovation pipeline, this aerospace win could serve as a template for similar wins in defense, medical devices, or industrial automation—sectors with strong secular demand and limited competition. The market appears to be underestimating the scalability of this model, focusing instead on near-term headwinds in healthcare and release liners, while overlooking how these new verticals can not only offset weakness but redefine the growth trajectory of the overall portfolio. With gross margins in specialty films historically exceeding 30% and the company’s proven ability to pass through input cost inflation, this vertical has the potential to significantly lift consolidated EBITDA margins beyond current levels if scaled successfully over the next 12–18 months.
Mativ’s disciplined capital allocation and balance sheet strengthening efforts are creating a latent financial flexibility that could unlock significant value through strategic acquisitions or shareholder returns once leverage targets are met. The company successfully refinanced its debt structure in April 2026, reducing bank group participants from 15 to 8, eliminating its delayed draw term loan, and securing maturities extending to 2031 and 2033—effectively removing near-term refinancing risk. This move, combined with a clear deleveraging path toward a 2.5–3.5x net leverage target (down from 4.1x as of Q1 2026), suggests that Mativ is transitioning from a survival and stabilization phase to one where excess cash flow can be redirected toward growth initiatives. Management has explicitly stated that debt reduction is the primary capital allocation priority, but once leverage reaches the target range—potentially by late 2026 or early 2027 given current free cash flow trends—the company will have meaningful flexibility to pursue tuck-in acquisitions in adjacent specialty materials segments or increase shareholder returns via dividends or buybacks. The market is likely undervaluing this optionality, particularly given Mativ’s history of generating over $90 million in annual free cash flow even during challenging periods, as demonstrated in 2025. With improved working capital efficiency and a renewed focus on capital discipline, the company could generate over $100 million in annual free cash flow by 2027, creating a substantial war chest for value-accretive moves that are not currently priced into the stock.
The company’s pricing agility and structured approach to inflation pass-through are not merely defensive tactics but are evolving into a sustainable competitive advantage that protects margins and enhances long-term value creation, a factor the market is underappreciating amid macroeconomic noise. Mativ has demonstrated a consistent ability to anticipate and respond to input cost inflation—implementing pricing actions in January 2026 for expected inflation and adding incremental actions in Q1 after the mid-quarter revision of its inflation forecast from $20–25 million to $40–50 million for the year. This proactive, layered approach ensures that margin erosion is minimized even during volatile periods, and management explicitly framed pricing as a long-term component of its customer and shareholder value proposition, enabling customer innovation and stabilizing financial results. Unlike peers that react slowly or incompletely to cost pressures, Mativ’s dual focus on short-term margin protection and long-term value creation through pricing discipline suggests it can maintain or expand its adjusted EBITDA margin trajectory even if input costs remain elevated. The market is likely treating this as a temporary headwind rather than recognizing that Mativ’s pricing framework—supported by its value-based selling approach and deep customer collaboration—is a structural strength that will continue to deliver margin resilience and support incremental pricing power in premium applications, thereby supporting sustained profitability beyond the current cycle.

Mativ’s recent strategic initiatives are positioning the company for accelerated growth in high-margin adjacent markets, particularly through its new aerospace specialty films commitment, which management confirmed will begin contributing in Q2 2026 and ramp through the second half of the year. This development exemplifies the company’s ability to leverage existing process capabilities and technical expertise to enter premium applications where its materials enable critical performance in life-saving or high-reliability systems. Unlike commoditized segments, aerospace applications typically command pricing power, longer contract durations, and lower elasticity to economic cycles, offering a structural shift toward higher-margin revenue streams. The fact that this win emerged from cross-functional collaboration signals that Mativ’s R&D and commercial teams are now effectively aligned to identify and capture white space opportunities, a capability that was historically underutilized. As the company continues to prioritize high-return projects in its innovation pipeline, this aerospace win could serve as a template for similar wins in defense, medical devices, or industrial automation—sectors with strong secular demand and limited competition. The market appears to be underestimating the scalability of this model, focusing instead on near-term headwinds in healthcare and release liners, while overlooking how these new verticals can not only offset weakness but redefine the growth trajectory of the overall portfolio. With gross margins in specialty films historically exceeding 30% and the company’s proven ability to pass through input cost inflation, this vertical has the potential to significantly lift consolidated EBITDA margins beyond current levels if scaled successfully over the next 12–18 months.
Mativ’s disciplined capital allocation and balance sheet strengthening efforts are creating a latent financial flexibility that could unlock significant value through strategic acquisitions or shareholder returns once leverage targets are met. The company successfully refinanced its debt structure in April 2026, reducing bank group participants from 15 to 8, eliminating its delayed draw term loan, and securing maturities extending to 2031 and 2033—effectively removing near-term refinancing risk. This move, combined with a clear deleveraging path toward a 2.5–3.5x net leverage target (down from 4.1x as of Q1 2026), suggests that Mativ is transitioning from a survival and stabilization phase to one where excess cash flow can be redirected toward growth initiatives. Management has explicitly stated that debt reduction is the primary capital allocation priority, but once leverage reaches the target range—potentially by late 2026 or early 2027 given current free cash flow trends—the company will have meaningful flexibility to pursue tuck-in acquisitions in adjacent specialty materials segments or increase shareholder returns via dividends or buybacks. The market is likely undervaluing this optionality, particularly given Mativ’s history of generating over $90 million in annual free cash flow even during challenging periods, as demonstrated in 2025. With improved working capital efficiency and a renewed focus on capital discipline, the company could generate over $100 million in annual free cash flow by 2027, creating a substantial war chest for value-accretive moves that are not currently priced into the stock.
The company’s pricing agility and structured approach to inflation pass-through are not merely defensive tactics but are evolving into a sustainable competitive advantage that protects margins and enhances long-term value creation, a factor the market is underappreciating amid macroeconomic noise. Mativ has demonstrated a consistent ability to anticipate and respond to input cost inflation—implementing pricing actions in January 2026 for expected inflation and adding incremental actions in Q1 after the mid-quarter revision of its inflation forecast from $20–25 million to $40–50 million for the year. This proactive, layered approach ensures that margin erosion is minimized even during volatile periods, and management explicitly framed pricing as a long-term component of its customer and shareholder value proposition, enabling customer innovation and stabilizing financial results. Unlike peers that react slowly or incompletely to cost pressures, Mativ’s dual focus on short-term margin protection and long-term value creation through pricing discipline suggests it can maintain or expand its adjusted EBITDA margin trajectory even if input costs remain elevated. The market is likely treating this as a temporary headwind rather than recognizing that Mativ’s pricing framework—supported by its value-based selling approach and deep customer collaboration—is a structural strength that will continue to deliver margin resilience and support incremental pricing power in premium applications, thereby supporting sustained profitability beyond the current cycle.

▼ Bear case

Mativ’s healthcare vertical continues to face structural demand headwinds that are being underestimated by management, with customer destocking and post-launch inventory normalization creating a prolonged drag that may extend well beyond the near-term, despite optimistic commentary about offsetting growth in other segments. While the company attributes Q1 weakness to temporary factors like customer inventory adjustments and a resolved plant outage in Knoxville, the persistence of these dynamics—especially in a post-pandemic normalization phase where healthcare providers and device manufacturers are right-sizing inventories after periods of overstocking—suggests a more durable shift in demand patterns. Management’s reliance on diversification as a buffer assumes that growth in filtration, films, and industrial applications can fully compensate, but these segments are themselves exposed to cyclical industrial activity and may not provide sufficient offset if healthcare weakness persists or worsens. Furthermore, the aerospace specialty films win, while promising, remains unquantified in terms of revenue contribution and timeline, with management citing confidentiality to avoid specificity—raising the risk that the opportunity is smaller or slower to materialize than implied. If healthcare demand does not rebound as expected and adjacent growth fails to materialize at scale, the company could face a prolonged period of stagnant or declining top-line performance, undermining the narrative of a growth-oriented strategic transformation.
Despite progress in deleveraging, Mativ’s balance sheet remains highly leveraged relative to peers and its historical performance, leaving it vulnerable to further interest rate volatility or unexpected cash flow disruptions that could derail its financial flexibility plans. Although the company reduced its bank group from 15 to 8 and extended debt maturities, its net leverage of 4.1x as of Q1 2026 remains significantly above the 2.5–3.5x target range and well above the sub-3.0x levels typical for investment-grade specialty materials peers. The company’s interest expense is projected at approximately $76 million annually under the new structure, which, while only slightly higher than the prior estimate, represents a substantial fixed cost burden relative to its Q1 2026 annualized EBITDA of roughly $190 million. This leaves minimal cushion for error—if free cash flow generation falters due to prolonged demand weakness, unexpected CapEx needs, or working capital reversals, the company may be forced to delay deleveraging or even consider dilutive financing options. The market may be assuming a smooth path to leverage targets, but any macroeconomic setback—such as a sharper-than-expected downturn in industrial end markets or prolonged input cost volatility—could extend the deleveraging timeline, increasing financial risk and constraining strategic options.
Mativ’s pricing strategy, while effective in the short term, carries inherent risks of demand destruction and customer pushback, particularly if input costs remain elevated or if competitors gain share through more aggressive innovation or cost structures, a dynamic the company has not adequately addressed in its forward-looking commentary. Management has emphasized its ability to pass through inflation via sequential pricing actions, but this approach assumes that customers have limited alternatives and that price increases will not trigger volume loss, substitution, or delayed purchases—especially in price-sensitive segments like release liners, labels, and certain industrial films. In healthcare, where customers are already destocking and under pricing pressure themselves, further increases could exacerbate volume declines. Moreover, the company’s reliance on pricing to offset inflation does not address the root cause of margin pressure; if input costs remain structurally higher due to geopolitical factors, sustained price hikes may erode competitiveness over time, particularly against lower-cost producers or those with better integrated supply chains. The market may be accepting the narrative that pricing power is durable, but if volume decline accelerates faster than price increases can compensate—especially in a weakening macro environment—the company could face a classic stagflationary scenario where rising costs fall on stagnant or declining sales, undermining both revenue and margin expansion efforts.

Mativ’s healthcare vertical continues to face structural demand headwinds that are being underestimated by management, with customer destocking and post-launch inventory normalization creating a prolonged drag that may extend well beyond the near-term, despite optimistic commentary about offsetting growth in other segments. While the company attributes Q1 weakness to temporary factors like customer inventory adjustments and a resolved plant outage in Knoxville, the persistence of these dynamics—especially in a post-pandemic normalization phase where healthcare providers and device manufacturers are right-sizing inventories after periods of overstocking—suggests a more durable shift in demand patterns. Management’s reliance on diversification as a buffer assumes that growth in filtration, films, and industrial applications can fully compensate, but these segments are themselves exposed to cyclical industrial activity and may not provide sufficient offset if healthcare weakness persists or worsens. Furthermore, the aerospace specialty films win, while promising, remains unquantified in terms of revenue contribution and timeline, with management citing confidentiality to avoid specificity—raising the risk that the opportunity is smaller or slower to materialize than implied. If healthcare demand does not rebound as expected and adjacent growth fails to materialize at scale, the company could face a prolonged period of stagnant or declining top-line performance, undermining the narrative of a growth-oriented strategic transformation.
Despite progress in deleveraging, Mativ’s balance sheet remains highly leveraged relative to peers and its historical performance, leaving it vulnerable to further interest rate volatility or unexpected cash flow disruptions that could derail its financial flexibility plans. Although the company reduced its bank group from 15 to 8 and extended debt maturities, its net leverage of 4.1x as of Q1 2026 remains significantly above the 2.5–3.5x target range and well above the sub-3.0x levels typical for investment-grade specialty materials peers. The company’s interest expense is projected at approximately $76 million annually under the new structure, which, while only slightly higher than the prior estimate, represents a substantial fixed cost burden relative to its Q1 2026 annualized EBITDA of roughly $190 million. This leaves minimal cushion for error—if free cash flow generation falters due to prolonged demand weakness, unexpected CapEx needs, or working capital reversals, the company may be forced to delay deleveraging or even consider dilutive financing options. The market may be assuming a smooth path to leverage targets, but any macroeconomic setback—such as a sharper-than-expected downturn in industrial end markets or prolonged input cost volatility—could extend the deleveraging timeline, increasing financial risk and constraining strategic options.
Mativ’s pricing strategy, while effective in the short term, carries inherent risks of demand destruction and customer pushback, particularly if input costs remain elevated or if competitors gain share through more aggressive innovation or cost structures, a dynamic the company has not adequately addressed in its forward-looking commentary. Management has emphasized its ability to pass through inflation via sequential pricing actions, but this approach assumes that customers have limited alternatives and that price increases will not trigger volume loss, substitution, or delayed purchases—especially in price-sensitive segments like release liners, labels, and certain industrial films. In healthcare, where customers are already destocking and under pricing pressure themselves, further increases could exacerbate volume declines. Moreover, the company’s reliance on pricing to offset inflation does not address the root cause of margin pressure; if input costs remain structurally higher due to geopolitical factors, sustained price hikes may erode competitiveness over time, particularly against lower-cost producers or those with better integrated supply chains. The market may be accepting the narrative that pricing power is durable, but if volume decline accelerates faster than price increases can compensate—especially in a weakening macro environment—the company could face a classic stagflationary scenario where rising costs fall on stagnant or declining sales, undermining both revenue and margin expansion efforts.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LIN	Linde Plc	237.95 Bn	33.52	6.87	24.68 Bn
2	SHW	Sherwin Williams Co	78.17 Bn	30.07	3.27	11.70 Bn
3	ECL	Ecolab Inc.	76.02 Bn	30.01	4.73	8.24 Bn
4	APD	Air Products & Chemicals, Inc.	66.38 Bn	47.14	5.33	17.40 Bn
5	PPG	Ppg Industries Inc	26.02 Bn	3,717.41	1.61	7.83 Bn
6	LYB	LyondellBasell Industries N.V.	22.51 Bn	-28.53	0.76	11.45 Bn
7	SQM	Chemical & Mining Co Of Chile Inc	19.70 Bn	21.77	3.72	4.79 Bn
8	IFF	International Flavors & Fragrances Inc	19.51 Bn	-102.16	1.81	5.82 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password